News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Gautam Mehta summarizes the FDA accelerated approval of fam-trastuzumab deruxtecan-nxki for HER2-mutated NSCLC
Photo from Gautam Mehta/X
Jul 19, 2024, 22:19

Gautam Mehta summarizes the FDA accelerated approval of fam-trastuzumab deruxtecan-nxki for HER2-mutated NSCLC

FDA oncology shared on X:

“OCE’s Gautam Mehta and colleagues summarize the FDA accelerated approval of fam-trastuzumab deruxtecan-nxki—the first targeted treatment option for patients with HER2-mutated non-small cell lung cancer – via The Oncologist Journal.”

fam-trastuzumab deruxtecan-nxki

FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations

Autors: Gautam U Mehta, Paz J Vellanki, Yi Ren, Anup K Amatya, Pallavi S Mishra-Kalyani, Lili Pan, Jeanne F Zirkelbach, Yuzhuo Pan, Jiang Liu, Stephanie L Aungst, Claudia P Miller, Mirat Shah, Nam Atiqur Rahman, Marc Theoret, Paul Kluetz, Richard Pazdur, Julia A Beaver, Harpreet Singh

fam-trastuzumab deruxtecan-nxki

Source: FDA Oncology/X

 

Anup K Amatya cancer Claudia P Miller FDA Oncology Gautam Mehta Gautam U Mehta Harpreet Singh HER2 gene HER2 mutant NSCLC Jeanne F Zirkelbach Jiang Liu Julia A Beaver Lili Pan Marc Theoret Mirat Shah Nam Atiqur Rahman OncoDaily Oncology Pallavi S Mishra-Kalyani Paul Kluetz Paz J Vellanki Richard Pazdur Stephanie L Aungst The Oncologist Journal Yi Ren Yuzhuo Pan
Special Coverage
Blog
Dec 21, 2024, 14:06
The Accelerate 2025 Annual Conference Agenda Is Here!
Blog
Dec 21, 2024, 14:03
Pioneer the future of discovery and innovation with a fully funded Bicentenary PhD Studentship at The University of Manchester
Blog
Dec 21, 2024, 14:00
NCI Division of Cancer Prevention - DHT Derived Biomarkers and COAs for Remote Monitoring and Endpoint Development
Blog
Dec 21, 2024, 13:51
The ESMO President Letter emphasises the importance of collective action to shape the future of oncology
Blog
Dec 21, 2024, 13:48
Overcoming recurrence: How research is bringing new hope for breast cancer patients - The Institute of Cancer Research
Blog
Dec 21, 2024, 13:46
IARC - Cancer Incidence in Five Continents, Vol XII
Blog
Dec 21, 2024, 13:43
National University Cancer Institute, Singapore clinicians had the exciting opportunity to present their work at the ESMO Asia 2024
Blog
Dec 21, 2024, 13:40
UICC - Welcoming the newest member, The World Hepatitis Alliance
Blog
Dec 21, 2024, 13:35
Pediatric Cancer and Blood Disorders Center of Armenia - Prioritizing the continuous education and knowledge exchange of the medical staff
Blog
Dec 21, 2024, 13:33
SIOP Europe - International Childhood Cancer Day 2025
Blog
Dec 21, 2024, 13:29
Canadian Cancer Society - How 5 organizations are working to take on cancer’s biggest issues
Radiotherapy
Dec 21, 2024, 13:20
What Is Flash Radiotherapy and How It Works? Pros and Cons